Drug intelligence / Profile preview

RU82197

Development stage: Unknown
Modality: Small Molecules

Overview

RU82197 is an experimental small molecule compound classified as a dipeptide derivative. Its chemical formula is C32H33N3O6 and it has a molecular weight of approximately 555.6 g/mol[1][3][4]. The compound has not been approved for any medical use and there are no known clinical trials in advanced phases; it is listed as experimental with no current indications or approvals[1][4]. Detailed information about its mechanism of action or therapeutic targets is not available in the referenced sources.

Other names: 4-[2-acetylamino-2-(1-biphenyl-4-ylmethyl-2-oxo-azepan-3-ylcarbamoyl)-ethyl]-2-formyl-benzoic acid4-(2-acetylamino-2-(1-biphenyl-4-ylmethyl-2-oxoazepan-3-ylcarbamoyl)-ethyl)-2-formyl-benzoic acid4-(2S)-2-{[(3S)-1-{[1,1'-biphenyl]-4-yImethyI}-2-oхoazepan -3-yI]carbamoyl}-2-acetamidoethyI]- 2-formyIbenzoic acid

Beyond the preview

Go deeper on RU82197.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RU82197.

Explore the full profile